Zou Zhongyu, Wei Jiangbo, Chen Yantao, Kang Yunhee, Shi Hailing, Yang Fan, Shi Zhuoyue, Chen Shijie, Zhou Ying, Sepich-Poore Caraline, Zhuang Xiaoxi, Zhou Xiaoming, Jiang Hualiang, Wen Zhexing, Jin Peng, Luo Cheng, He Chuan
Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA; Howard Hughes Medical Institute, The University of Chicago, Chicago, IL 60637, USA.
The Center for Chemical Biology, Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Mol Cell. 2023 Dec 7;83(23):4304-4317.e8. doi: 10.1016/j.molcel.2023.10.028. Epub 2023 Nov 9.
RNA-binding proteins (RBPs) control messenger RNA fate in neurons. Here, we report a mechanism that the stimuli-induced neuronal translation is mediated by phosphorylation of a YTHDF1-binding protein FMRP. Mechanistically, YTHDF1 can condense with ribosomal proteins to promote the translation of its mRNA targets. FMRP regulates this process by sequestering YTHDF1 away from the ribosome; upon neuronal stimulation, FMRP becomes phosphorylated and releases YTHDF1 for translation upregulation. We show that a new small molecule inhibitor of YTHDF1 can reverse fragile X syndrome (FXS) developmental defects associated with FMRP deficiency in an organoid model. Our study thus reveals that FMRP and its phosphorylation are important regulators of activity-dependent translation during neuronal development and stimulation and identifies YTHDF1 as a potential therapeutic target for FXS in which developmental defects caused by FMRP depletion could be reversed through YTHDF1 inhibition.
Mol Cell. 2023-12-7
Int J Mol Sci. 2022-10-6
Mol Cell Biol. 2019-2-4
Proc Natl Acad Sci U S A. 2016-6-28
Nat Neurosci. 2013-4-14
Hum Mol Genet. 2001-2-15
J Immunother Cancer. 2025-9-3
ACS Bio Med Chem Au. 2025-6-27
Front Oncol. 2025-8-1
Mol Cell. 2025-7-8
J Exp Med. 2025-8-4
Front Pharmacol. 2025-4-28
Genome Biol. 2023-1-24
Sci Adv. 2022-2-18
Cell Stem Cell. 2020-5-7